Latest Breaking News On - Cassava science - Page 5 : comparemela.com

Cassava Sciences stock gains on dividend plans (NASDAQ:SAVA)

Cassava Sciences stock gains on dividend plans (NASDAQ:SAVA)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Remi barbierSaranya yuenyongCassava sciencesCassava science

Cassava Sciences Announces Dividend Distribution of

Cassava Sciences Announces Dividend Distribution of
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkRemi barbierEric schoenDunn crutcherCassava sciences incDetails of bonus share programCassava sciencesExchange commissionRecord will receive warrantsPurchase sharesCommon stockShareholders freeAre expectedHolders who chooseExercise during

Cassava Sciences: How To Interpret 3 Positive Updates Shared In Q3 (NASDAQ:SAVA)

Cassava Sciences: How To Interpret 3 Positive Updates Shared In Q3 (NASDAQ:SAVA)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesEli lillyHoau yan wangRichardj barryRemi barbierInternational journal of molecular sciencesCassava sciences incBiogen incDrug administrationUniversity of milanCassava sciencesAlzheimer associationCity university new yorkNew york timesYale university

Alzheimer s Disease Drug Development: Another Lost Year

Alzheimer s Disease Drug Development: Another Lost Year
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

United statesEli lillyInmune bio inmb xproAlzheimer associationEuropean medicines agencyJournal of ginseng researchDrug administrationFull moon risingSkyline silhouetteAntibody drugCassava scienceModifying treatmentsDisease modifyingEuropean medicinesGinseng researchCyclo trappsol

Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results

Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimer s.Over 1,900 patients randomized in on-going Phase 3 trials.Top-line results for 52-week Phase 3 trial expected.

United statesRemi barbierEric schoenCassava sciences incCassava sciencesCassava scienceSafety monitoring boardThird quarterMore information contactChief financialNote regarding forward looking statementsPrivate securities litigation reform actAnnual reportFinancial tables follow